Nasdaq · CIK 0001737953
REPL Replimune Group, Inc.
Insider trading from SEC Form 4. Last filing May 22, 2025. Close $13.42 on Oct 9, 2026, +689% from the 52-week low and -16% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
REPLOct 9, 2026 · close 13.42
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Replimune Group, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Philip Astley-Sparke director sell | $260k 32,279 shares | -2% | +33% from low-38% from high | |
| 37Weak | Emily Luisa Hill Chief Financial Officer sell | $20k 2,535 shares | -2% | +33% from low-38% from high | |
| 52Moderate | Sushil Patel Chief Executive Officer sell | $202k 25,105 shares | -7% | +33% from low-38% from high | |
| 35Weak | Christopher Sarchi Chief Commercial Officer sell | $30k 3,749 shares | -3% | +33% from low-38% from high | |
| 35Weak | Andrew Schwendenman Chief Accounting Officer sell | $26k 3,287 shares | -5% | +33% from low-38% from high | |
| 38Weak | Konstantinos Xynos Chief Medical Officer sell | $64k 7,952 shares | -5% | +33% from low-38% from high | |
| 15Weak | Sushil Patel Chief Executive Officer sell | $124k 10,000 shares | -5% | - | |
| 30Weak | Christopher Sarchi Chief Commercial Officer sell | $56k 5,207 shares | -6% | - | |
| 32Weak | Konstantinos Xynos Chief Medical Officer sell | $78k 7,246 shares | -6% | - |
Transactions
The last 28 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 20, 2025 | Emily Luisa Hill Chief Financial Officer | SOpen-market sale Common Stock | -2,535 | $8.05 | $20k | 143,522 | May 22, 2025 |
| May 20, 2025 | Sushil Patel Chief Executive Officer | SOpen-market sale Common Stock | -25,105 | $8.06 | $202k | 343,576 | May 22, 2025 |
| May 20, 2025 | Christopher Sarchi Chief Commercial Officer | SOpen-market sale Common Stock | -3,749 | $8.05 | $30k | 128,296 | May 22, 2025 |
| May 20, 2025 | Andrew Schwendenman Chief Accounting Officer | SOpen-market sale Common Stock | -3,287 | $8.05 | $26k | 68,284 | May 22, 2025 |
| May 20, 2025 | Konstantinos Xynos Chief Medical Officer | SOpen-market sale Common Stock | -7,952 | $8.06 | $64k | 146,933 | May 22, 2025 |
| May 20, 2025 | Philip Astley-Sparke director | SOpen-market sale Common Stock | -32,279 | $8.06 | $260k | 1,405,071 | May 22, 2025 |
| Apr 1, 2025 | Paolo Pucci director | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Apr 1, 2025 | Konstantinos Xynos Chief Medical Officer | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 154,885 | Apr 3, 2025 |
| Apr 1, 2025 | Joseph P Slattery director | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Apr 1, 2025 | Dieter Weinand director | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Apr 1, 2025 | Christopher Sarchi Chief Commercial Officer | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 132,045 | Apr 3, 2025 |
| Apr 1, 2025 | Andrew Schwendenman Chief Accounting Officer | AGrant or award Common Stock | -33,333 | $0.00 | $0 | 71,571 | Apr 3, 2025 |
| Apr 1, 2025 | Veleka Peeples-Dyer director | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Apr 1, 2025 | Sushil Patel Chief Executive Officer | AGrant or award Common Stock | +166,667 | $0.00 | $0 | 368,681 | Apr 3, 2025 |
| Apr 1, 2025 | Christy J. Oliger director | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Apr 1, 2025 | Emily Luisa Hill Chief Financial Officer | AGrant or award Common Stock | +45,000 | $0.00 | $0 | 146,057 | Apr 3, 2025 |
| Apr 1, 2025 | Kapil Dhingra director | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Apr 1, 2025 | Madhavan Balachandran director | AGrant or award Stock Option (right to buy)derivative | +32,000 | $0.00 | $0 | 32,000 | Apr 3, 2025 |
| Apr 1, 2025 | Sushil Patel Chief Executive Officer | AGrant or award Employee Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Apr 3, 2025 |
| Apr 1, 2025 | Andrew Schwendenman Chief Accounting Officer | AGrant or award Employee Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Apr 3, 2025 |
| Apr 1, 2025 | Emily Luisa Hill Chief Financial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +67,500 | $0.00 | $0 | 67,500 | Apr 3, 2025 |
| Apr 1, 2025 | Christopher Sarchi Chief Commercial Officer | AGrant or award Employee Stock Option (right to buy)derivative | +67,500 | $0.00 | $0 | 67,500 | Apr 3, 2025 |
| Apr 1, 2025 | Konstantinos Xynos Chief Medical Officer | AGrant or award Employee Stock Option (right to buy)derivative | +67,500 | $0.00 | $0 | 67,500 | Apr 3, 2025 |
| Mar 5, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Non-Qualified Stock Option (right to buy)uy)derivativeindirect: See Footnotes | +64,000 | $0.00 | $0 | 64,000 | Mar 7, 2025 |
| Mar 5, 2025 | Baker Bros. Advisors LP director, owner | AGrant or award Non-Qualified Stock Option (right to buy)uy)derivativeindirect: See Footnotes | +64,000 | $0.00 | $0 | 64,000 | Mar 7, 2025 |
| Dec 16, 2024 | Sushil Patel Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -10,000 | $12.42 | $124k | 202,014 | Dec 18, 2024 |
| Nov 18, 2024 | Christopher Sarchi Chief Commercial Officer | SOpen-market sale Common Stock | -5,207 | $10.78 | $56k | 87,045 | Nov 20, 2024 |
| Nov 18, 2024 | Konstantinos Xynos Chief Medical Officer | SOpen-market sale Common Stock | -7,246 | $10.78 | $78k | 109,885 | Nov 20, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Philip Astley-Sparkedirector
- Baker Bros. Advisors LPdirector, owner, other
- Madhavan Balachandrandirector
- Kapil Dhingradirector
- Emily Luisa HillChief Financial Officer
- Christy J. Oligerdirector
- Sushil PatelChief Executive Officer
- Veleka Peeples-Dyerdirector
- Paolo Puccidirector
- Joseph P Slatterydirector
- Christopher SarchiChief Commercial Officer
- Andrew SchwendenmanChief Accounting Officer
- Dieter Weinanddirector
- Konstantinos XynosChief Medical Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.